Sangamo Therapeutics, Inc. (SGMO)
USD 0.58
(-11.68%)
USD 0.58
(-11.68%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 228.68 Million USD | -14.16% |
| 2022 | 312.58 Million USD | 6.31% |
| 2021 | 294.03 Million USD | 18.69% |
| 2020 | 247.74 Million USD | 19.33% |
| 2019 | 207.6 Million USD | 28.47% |
| 2018 | 161.6 Million USD | 73.9% |
| 2017 | 92.92 Million USD | 1.07% |
| 2016 | 91.94 Million USD | 6.43% |
| 2015 | 86.39 Million USD | 19.3% |
| 2014 | 72.42 Million USD | 42.62% |
| 2013 | 50.77 Million USD | 15.79% |
| 2012 | 43.85 Million USD | -4.96% |
| 2011 | 46.14 Million USD | 0.87% |
| 2010 | 45.74 Million USD | 9.98% |
| 2009 | 41.58 Million USD | 0.07% |
| 2008 | 41.56 Million USD | 22.71% |
| 2007 | 33.86 Million USD | 18.37% |
| 2006 | 28.61 Million USD | 76.28% |
| 2005 | 16.23 Million USD | 1.67% |
| 2004 | 15.96 Million USD | 11.27% |
| 2003 | 14.34 Million USD | -59.63% |
| 2002 | 35.53 Million USD | 75.37% |
| 2001 | 20.26 Million USD | -4.18% |
| 2000 | 21.14 Million USD | 211.0% |
| 1999 | 6.8 Million USD | 23.73% |
| 1998 | 5.49 Million USD | 120.1% |
| 1997 | 2.49 Million USD | 162.84% |
| 1996 | 950 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 31.82 Million USD | -26.56% |
| 2024 Q1 | 43.33 Million USD | -29.45% |
| 2023 Q4 | 61.42 Million USD | -13.5% |
| 2023 Q1 | 81.35 Million USD | -1.54% |
| 2023 Q3 | 71 Million USD | -10.19% |
| 2023 Q2 | 79.06 Million USD | -2.82% |
| 2023 FY | 268.33 Million USD | -14.16% |
| 2022 Q4 | 82.62 Million USD | 1.56% |
| 2022 Q3 | 81.35 Million USD | 8.31% |
| 2022 FY | 312.58 Million USD | 6.31% |
| 2022 Q1 | 73.49 Million USD | 8.26% |
| 2022 Q2 | 75.11 Million USD | 2.2% |
| 2021 Q2 | 76.57 Million USD | 5.5% |
| 2021 Q1 | 72.58 Million USD | 4.84% |
| 2021 FY | 294.03 Million USD | 18.69% |
| 2021 Q3 | 76.99 Million USD | 0.56% |
| 2021 Q4 | 67.88 Million USD | -11.84% |
| 2020 Q3 | 61.46 Million USD | 3.39% |
| 2020 Q1 | 57.59 Million USD | 7.9% |
| 2020 Q2 | 59.45 Million USD | 3.22% |
| 2020 Q4 | 69.23 Million USD | 12.64% |
| 2020 FY | 247.74 Million USD | 19.33% |
| 2019 Q4 | 53.38 Million USD | 4.25% |
| 2019 Q2 | 51.05 Million USD | -1.76% |
| 2019 Q1 | 51.96 Million USD | 9.16% |
| 2019 FY | 207.6 Million USD | 28.47% |
| 2019 Q3 | 51.2 Million USD | 0.3% |
| 2018 Q4 | 47.6 Million USD | 19.61% |
| 2018 FY | 161.6 Million USD | 73.9% |
| 2018 Q1 | 33.63 Million USD | 25.3% |
| 2018 Q2 | 40.55 Million USD | 20.58% |
| 2018 Q3 | 39.8 Million USD | -1.86% |
| 2017 FY | 92.92 Million USD | 1.07% |
| 2017 Q3 | 24.84 Million USD | 18.2% |
| 2017 Q1 | 20.21 Million USD | 7.81% |
| 2017 Q2 | 21.02 Million USD | 3.98% |
| 2017 Q4 | 26.84 Million USD | 8.03% |
| 2016 FY | 91.94 Million USD | 6.43% |
| 2016 Q1 | 20.62 Million USD | -16.82% |
| 2016 Q2 | 30.54 Million USD | 48.11% |
| 2016 Q3 | 22.02 Million USD | -27.88% |
| 2016 Q4 | 18.75 Million USD | -14.88% |
| 2015 Q1 | 19.71 Million USD | 2.02% |
| 2015 Q2 | 20.63 Million USD | 4.68% |
| 2015 Q3 | 21.25 Million USD | 3.0% |
| 2015 Q4 | 24.79 Million USD | 16.66% |
| 2015 FY | 86.39 Million USD | 19.3% |
| 2014 Q1 | 15.67 Million USD | 4.63% |
| 2014 Q4 | 19.32 Million USD | -3.5% |
| 2014 Q3 | 20.02 Million USD | 15.05% |
| 2014 FY | 72.42 Million USD | 42.62% |
| 2014 Q2 | 17.4 Million USD | 11.0% |
| 2013 Q2 | 12.4 Million USD | 7.58% |
| 2013 Q1 | 11.52 Million USD | -6.28% |
| 2013 FY | 50.77 Million USD | 15.79% |
| 2013 Q4 | 14.98 Million USD | 26.27% |
| 2013 Q3 | 11.86 Million USD | -4.32% |
| 2012 Q3 | 10.7 Million USD | 3.79% |
| 2012 Q1 | 10.52 Million USD | -5.29% |
| 2012 FY | 43.85 Million USD | -4.96% |
| 2012 Q4 | 12.3 Million USD | 14.86% |
| 2012 Q2 | 10.31 Million USD | -1.97% |
| 2011 Q2 | 11.79 Million USD | -0.05% |
| 2011 FY | 46.14 Million USD | 0.87% |
| 2011 Q4 | 11.11 Million USD | -2.78% |
| 2011 Q1 | 11.8 Million USD | -9.41% |
| 2011 Q3 | 11.43 Million USD | -3.09% |
| 2010 FY | 45.74 Million USD | 9.98% |
| 2010 Q1 | 10.65 Million USD | -15.84% |
| 2010 Q2 | 10.4 Million USD | -2.32% |
| 2010 Q3 | 11.65 Million USD | 12.05% |
| 2010 Q4 | 13.02 Million USD | 11.74% |
| 2009 FY | 41.58 Million USD | 0.07% |
| 2009 Q2 | 9.88 Million USD | -2.93% |
| 2009 Q1 | 10.18 Million USD | 12.72% |
| 2009 Q4 | 12.65 Million USD | 42.73% |
| 2009 Q3 | 8.86 Million USD | -10.29% |
| 2008 Q2 | 10.83 Million USD | -6.41% |
| 2008 Q1 | 11.57 Million USD | 11.56% |
| 2008 Q4 | 9.03 Million USD | -10.8% |
| 2008 Q3 | 10.12 Million USD | -6.5% |
| 2008 FY | 41.56 Million USD | 22.71% |
| 2007 Q2 | 8.42 Million USD | 13.37% |
| 2007 FY | 33.86 Million USD | 18.37% |
| 2007 Q1 | 7.42 Million USD | -38.09% |
| 2007 Q4 | 10.37 Million USD | 35.71% |
| 2007 Q3 | 7.64 Million USD | -9.24% |
| 2006 FY | 28.61 Million USD | 76.28% |
| 2006 Q3 | 5.42 Million USD | -7.3% |
| 2006 Q2 | 5.84 Million USD | 9.45% |
| 2006 Q1 | 5.34 Million USD | 23.79% |
| 2006 Q4 | 11.99 Million USD | 121.3% |
| 2005 FY | 16.23 Million USD | 1.67% |
| 2005 Q2 | 3.87 Million USD | 0.99% |
| 2005 Q3 | 4.2 Million USD | 8.52% |
| 2005 Q4 | 4.31 Million USD | 2.69% |
| 2005 Q1 | 3.83 Million USD | 6.59% |
| 2004 FY | 15.96 Million USD | 11.27% |
| 2004 Q2 | -3.26 Million USD | -181.83% |
| 2004 Q1 | 3.99 Million USD | 31.6% |
| 2004 Q4 | 3.59 Million USD | -25.75% |
| 2004 Q3 | 4.84 Million USD | 248.45% |
| 2003 Q4 | 3.03 Million USD | -12.7% |
| 2003 Q2 | 4.22 Million USD | 16.54% |
| 2003 Q1 | 3.62 Million USD | 3.52% |
| 2003 FY | 14.34 Million USD | -59.63% |
| 2003 Q3 | 3.47 Million USD | -17.72% |
| 2002 Q3 | 22.43 Million USD | 416.53% |
| 2002 Q4 | 3.49 Million USD | -84.4% |
| 2002 Q1 | 5.26 Million USD | -14.27% |
| 2002 Q2 | 4.34 Million USD | -17.46% |
| 2002 FY | 35.53 Million USD | 75.37% |
| 2001 Q3 | 5.86 Million USD | 27.46% |
| 2001 Q1 | 3.65 Million USD | -63.09% |
| 2001 Q4 | 6.13 Million USD | 4.62% |
| 2001 FY | 20.26 Million USD | -4.18% |
| 2001 Q2 | 4.6 Million USD | 25.87% |
| 2000 Q2 | 3.54 Million USD | -20.82% |
| 2000 FY | 21.14 Million USD | 211.0% |
| 2000 Q3 | 4.03 Million USD | 13.81% |
| 2000 Q4 | 9.9 Million USD | 145.33% |
| 2000 Q1 | 4.48 Million USD | 0.0% |
| 1999 FY | 6.8 Million USD | 23.73% |
| 1998 FY | 5.49 Million USD | 120.1% |
| 1997 FY | 2.49 Million USD | 162.84% |
| 1996 FY | 950 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 16.914% |
| Alkermes plc | 996.24 Million USD | 77.046% |
| Agenus Inc. | 78.18 Million USD | -192.493% |
| Aptorum Group Limited | 10.56 Thousand USD | -2164200.587% |
| Ardelyx, Inc. | 169.93 Million USD | -34.568% |
| Dyadic International, Inc. | 9.15 Million USD | -2398.499% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -927.637% |
| Lantern Pharma Inc. | 17.87 Million USD | -1179.145% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -3296.939% |
| Novavax, Inc. | 779.12 Million USD | 70.649% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -182.105% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -178.213% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -1077.639% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -672.411% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -330.445% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 39.899% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -840.814% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -503.871% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -643.167% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -169.937% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1209.962% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -35.767% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -599.007% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -43.116% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 87.296% |
| AlloVir, Inc. | 180.93 Million USD | -26.389% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 48.696% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -670.433% |
| Bicycle Therapeutics plc | 216.92 Million USD | -5.42% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -33.029% |
| ChromaDex Corporation | 56.37 Million USD | -305.612% |
| Chimerix, Inc. | 93.38 Million USD | -144.868% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1544.04% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -51.911% |
| CRISPR Therapeutics AG | 463.49 Million USD | 50.662% |
| Precision BioSciences, Inc. | 92.46 Million USD | -147.321% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 9.984% |
| Fortress Biotech, Inc. | 200.19 Million USD | -14.229% |
| Fortress Biotech, Inc. | 200.19 Million USD | -14.229% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -598.345% |
| ImmuCell Corporation | 9.61 Million USD | -2277.783% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -44.905% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1316.755% |
| Incyte Corporation | 1.19 Billion USD | 80.791% |
| Innoviva, Inc. | 132.15 Million USD | -73.041% |
| IO Biotech, Inc. | 91.44 Million USD | -150.079% |
| Jaguar Health, Inc. | 42.01 Million USD | -444.282% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -35.092% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -171.195% |
| ContextLogic Inc. | 387 Million USD | 40.91% |
| MiMedx Group, Inc. | 229.72 Million USD | 0.456% |
| MEI Pharma, Inc. | 34.78 Million USD | -557.41% |
| NextCure, Inc. | 67.63 Million USD | -238.099% |
| Onconetix, Inc. | 34.9 Million USD | -555.104% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1694.131% |
| Opthea Limited | 191.96 Million USD | -19.124% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -8210.846% |
| Vaxcyte, Inc. | 468.04 Million USD | 51.141% |
| PDS Biotechnology Corporation | 43.04 Million USD | -431.255% |
| Precigen, Inc. | 84.18 Million USD | -171.653% |
| Pharming Group N.V. | 225.49 Million USD | -1.414% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -36.259% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -215.134% |
| PureTech Health plc | 144.59 Million USD | -58.15% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -75.553% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 6.721% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -840.814% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -641.048% |
| Acelyrin, Inc. | 422.06 Million USD | 45.819% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1773438.08% |
| Summit Therapeutics Inc. | 87.68 Million USD | -160.794% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -516.987% |
| Senti Biosciences, Inc. | 94.7 Million USD | -141.466% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -85.087% |
| Elevation Oncology, Inc. | 45.44 Million USD | -403.202% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -676.002% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -5701.046% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -73.013% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -570.911% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -2605.952% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -26.133% |
| Seer, Inc. | 110.49 Million USD | -106.969% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -223.937% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -144.635% |
| ESSA Pharma Inc. | 32.13 Million USD | -611.643% |
| GlycoMimetics, Inc. | 39.28 Million USD | -482.101% |
| GT Biopharma, Inc. | 13.57 Million USD | -1584.443% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -4.026% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -13.706% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 11.851% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -302.896% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -322.855% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -2201.149% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 43.335% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -1108.093% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -351.108% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 11.931% |
| Aptose Biosciences Inc. | 52.35 Million USD | -336.779% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1486.912% |
| Soligenix, Inc. | 7.79 Million USD | -2833.581% |
| Century Therapeutics, Inc. | 56.07 Million USD | -307.84% |
| Kura Oncology, Inc. | 165.8 Million USD | -37.922% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -99.708% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -2648.888% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -9114.878% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -112.334% |
| Autolus Therapeutics plc | 196.72 Million USD | -16.243% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -170.125% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -96.371% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -1079.797% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 28.928% |
| GRI Bio, Inc. | 11.33 Million USD | -1918.358% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -3141.067% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -74.308% |
| IGM Biosciences, Inc. | 265.59 Million USD | 13.898% |
| INmune Bio, Inc. | 29.89 Million USD | -664.918% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -32.527% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -467.243% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1331.096% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1352.716% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -268.257% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -112.682% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 17.053% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 24.14% |
| Verastem, Inc. | 92.08 Million USD | -148.338% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1174.764% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -23.128% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -88.358% |
| Histogen Inc. | 14.27 Million USD | -1502.298% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1324.962% |
| Surrozen, Inc. | 18.55 Million USD | -1132.776% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1433.222% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4392.523% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -283.221% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -791.644% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -386.491% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -2896.0% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -28.374% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -372.012% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 6.663% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1388.165% |
| Apollomics, Inc. | 54.14 Million USD | -322.386% |
| Amarin Corporation plc | 272.35 Million USD | 16.037% |
| Mesoblast Limited | 5.9 Million USD | -3774.619% |
| Turnstone Biologics Corp. | 78.33 Million USD | -191.915% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 6.326% |
| Synaptogenix, Inc. | 8.31 Million USD | -2650.59% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1467.805% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 9.633% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -586.107% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -2489.445% |
| Exelixis, Inc. | 1.58 Billion USD | 85.588% |
| Better Therapeutics, Inc. | 38.26 Million USD | -497.669% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 1.452% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 73.26% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1836.807% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -2743.604% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -662.445% |
| Gritstone bio, Inc. | 148.37 Million USD | -54.124% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -232.089% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1297.781% |
| Avid Bioservices, Inc. | 25.99 Million USD | -779.674% |
| Insmed Incorporated | 949.26 Million USD | 75.91% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1357.509% |
| MediWound Ltd. | 18.86 Million USD | -1111.999% |
| OmniAb, Inc. | 83.89 Million USD | -172.579% |
| Alector, Inc. | 248.8 Million USD | 8.088% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 2.402% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -337.657% |
| Zai Lab Limited | 547.47 Million USD | 58.23% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 42.637% |
| Aura Biosciences, Inc. | 84.99 Million USD | -169.064% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 7.469% |
| Immunic, Inc. | 99.22 Million USD | -130.471% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -43.813% |
| Veracyte, Inc. | 357.93 Million USD | 36.111% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 97.464% |
| FibroGen, Inc. | 398.11 Million USD | 42.559% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1509.289% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -3220.002% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -3109.214% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 92.976% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -783.856% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 27.757% |
| TG Therapeutics, Inc. | 198.47 Million USD | -15.219% |
| Galecto, Inc. | 35.62 Million USD | -541.873% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -462.019% |
| Fortrea Holdings Inc. | 457.3 Million USD | 49.993% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -321.313% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -691.883% |
| XBiotech Inc. | 37.51 Million USD | -509.651% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -232.089% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -1007.463% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -60.973% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -130.815% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -106.546% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 76.136% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -692.789% |
| Vaxxinity, Inc. | 56.05 Million USD | -307.986% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 46.898% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -925.089% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -106.265% |
| NexImmune, Inc. | 28.16 Million USD | -711.857% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -4034.553% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1178.077% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 91.877% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -798.229% |
| Scopus BioPharma Inc. | 11.71 Million USD | -1852.048% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -79.975% |
| Ainos, Inc. | 12.95 Million USD | -1665.506% |
| Pluri Inc. | 22.48 Million USD | -917.26% |
| Prothena Corporation plc | 282.4 Million USD | 19.024% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -14.327% |
| Celularity Inc. | 215.05 Million USD | -6.334% |
| Rallybio Corporation | 78.93 Million USD | -189.718% |
| Cue Biopharma, Inc. | 19.54 Million USD | -1070.198% |
| MeiraGTx Holdings plc | 151.07 Million USD | -51.366% |
| Omeros Corporation | 94.75 Million USD | -141.348% |
| Humacyte, Inc. | 23.49 Million USD | -873.231% |
| Immunocore Holdings plc | 308.04 Million USD | 25.763% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -6645.723% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -163.259% |
| Blueprint Medicines Corporation | 722.86 Million USD | 68.365% |
| CalciMedica, Inc. | 21.81 Million USD | -948.173% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -206.295% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -42.444% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -33.501% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 22.466% |
| Pulmatrix, Inc. | 22.03 Million USD | -937.662% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -561.403% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -157.331% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 58.54% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -215.199% |
| Cytokinetics, Incorporated | 173.61 Million USD | -31.719% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -564.4% |
| Nutriband Inc. | 5.73 Million USD | -3888.119% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -424.339% |
| Vor Biopharma Inc. | 126.03 Million USD | -81.44% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 80.77% |
| Evogene Ltd. | 27.79 Million USD | -722.886% |
| ProKidney Corp. | 151.52 Million USD | -50.922% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -208.298% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -2872.865% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 62.769% |
| CorMedix Inc. | 48.95 Million USD | -367.096% |
| BioLineRx Ltd. | 50.8 Million USD | -350.14% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -51.745% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -500.651% |
| Atai Life Sciences N.V. | 125.78 Million USD | -81.802% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -180.11% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -180.903% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 9.452% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -598.473% |
| MediciNova, Inc. | 10.9 Million USD | -1997.931% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -77.519% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -3050.069% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3697.3% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 51.994% |
| Biomea Fusion, Inc. | 126.13 Million USD | -81.298% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 82.568% |
| Mereo BioPharma Group plc | 35.84 Million USD | -538.022% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -19.672% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 0.554% |
| Absci Corporation | 73.66 Million USD | -210.428% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -729.091% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -71.18% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 5.567% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 12.734% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -9.945% |
| Allakos Inc. | 196.05 Million USD | -16.64% |
| Imunon, Inc. | 20.31 Million USD | -1025.924% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -101.535% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 37.962% |
| BioAtla, Inc. | 129.68 Million USD | -76.332% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1836.807% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -1343.413% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -169.295% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -447.632% |
| XOMA Corporation | 46.46 Million USD | -392.177% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -105.701% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -60.519% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1661.923% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -120.614% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -32.284% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 10.238% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -511.313% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -2680.367% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1260.705% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -9956.421% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 23.6% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3298.561% |
| UroGen Pharma Ltd. | 138.88 Million USD | -64.651% |
| Sutro Biopharma, Inc. | 243 Million USD | 5.896% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -3043.531% |
| Orgenesis Inc. | 45.75 Million USD | -399.771% |
| Entera Bio Ltd. | 8.86 Million USD | -2481.038% |
| GH Research PLC | 41.22 Million USD | -454.752% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -789.529% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -175.342% |
| Xencor, Inc. | 306.97 Million USD | 25.506% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -4535.149% |
| Replimune Group, Inc. | 234.77 Million USD | 2.595% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -1016.063% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -19.231% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3298.561% |
| Portage Biotech Inc. | 18.19 Million USD | -1156.553% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -3050.069% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -117.871% |
| OncoCyte Corporation | 25.63 Million USD | -791.992% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -3651.554% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -1895.974% |
| Purple Biotech Ltd. | -22.46 Million USD | 1117.848% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1287.621% |
| scPharmaceuticals Inc. | 65.17 Million USD | -250.855% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -2605.396% |
| HilleVax, Inc. | 133.34 Million USD | -71.495% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -2123.432% |
| Tharimmune, Inc. | 9.45 Million USD | -2318.558% |
| Genprex, Inc. | 31.06 Million USD | -636.239% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -21.946% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -628.814% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -29792.81% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -4098.337% |
| OKYO Pharma Limited | 8243.57 USD | -2773940.859% |
| Savara Inc. | 15.74 Million USD | -1352.398% |
| Curis, Inc. | 58.35 Million USD | -291.877% |
| Daré Bioscience, Inc. | 33.6 Million USD | -580.405% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -4390.536% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -2965.005% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -746.273% |
| BeiGene, Ltd. | 3.28 Billion USD | 93.042% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -1046.881% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 54.151% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -48.83% |
| Erasca, Inc. | 141.52 Million USD | -61.583% |
| bluebird bio, Inc. | 240.23 Million USD | 4.809% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4951.498% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 86.905% |
| DBV Technologies S.A. | 92.16 Million USD | -148.134% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4951.498% |
| Moderna, Inc. | 6.39 Billion USD | 96.424% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -436.694% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1491.814% |
| Molecular Templates, Inc. | 63.09 Million USD | -262.461% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -242.843% |
| Travere Therapeutics, Inc. | 472 Million USD | 51.551% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -59.569% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -268.352% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -426.743% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -9.874% |
| MacroGenics, Inc. | 217.21 Million USD | -5.278% |
| RenovoRx, Inc. | 11.39 Million USD | -1906.669% |
| Adicet Bio, Inc. | 152.03 Million USD | -50.41% |
| Prime Medicine, Inc. | 186.63 Million USD | -22.525% |
| Aditxt, Inc. | 25.95 Million USD | -781.207% |
| Adagene Inc. | 41.83 Million USD | -446.671% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3028.275% |
| Quantum-Si incorporated | 111.65 Million USD | -104.802% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -33.07% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1468.69% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -538.379% |
| SciSparc Ltd. | 9.01 Million USD | -2437.787% |
| Vericel Corporation | 142.04 Million USD | -60.997% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2541.664% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -890.446% |
| Generation Bio Co. | 144.46 Million USD | -58.292% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -175.419% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -164.492% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 22.67% |
| Invivyd, Inc. | 205.75 Million USD | -11.142% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -216.911% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -2338.342% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -203.878% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -2123.0% |
| 2seventy bio, Inc. | 289.88 Million USD | 21.114% |
| ADMA Biologics, Inc. | 66.58 Million USD | -243.436% |
| Clene Inc. | 41.07 Million USD | -456.765% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1685.462% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -317.33% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3697.3% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 35.043% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -522.563% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -578.012% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -120.516% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -601.709% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -34.298% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 70.213% |
| Evaxion Biotech A/S | 22.27 Million USD | -926.852% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -68.713% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 2.64% |
| Trevena, Inc. | 38.41 Million USD | -495.319% |
| Surrozen, Inc. | 18.55 Million USD | -1132.776% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -186.047% |
| Cingulate Inc. | 22.75 Million USD | -904.781% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 3152.322% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -411.966% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -2677.285% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -122.976% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 69.675% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -268.399% |
| Clearmind Medicine Inc. | 8.74 Million USD | -2516.072% |
| Kronos Bio, Inc. | 128.11 Million USD | -78.492% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -172.005% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -7696.835% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -126.804% |
| Statera Biopharma, Inc. | 28.82 Million USD | -693.215% |
| ImmunityBio, Inc. | 362.87 Million USD | 36.981% |
| Korro Bio, Inc. | 84.53 Million USD | -170.518% |
| Kineta, Inc. | 21.15 Million USD | -980.923% |
| BioVie Inc. | 31.95 Million USD | -615.739% |
| Codexis, Inc. | 66.51 Million USD | -243.787% |
| Celularity Inc. | 215.05 Million USD | -6.334% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -0.909% |
| Celcuity Inc. | 66.23 Million USD | -245.28% |
| Virax Biolabs Group Limited | 6.54 Million USD | -3392.864% |
| Cibus, Inc. | 320.3 Million USD | 28.606% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -431.814% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -575.688% |
| IN8bio, Inc. | 30.33 Million USD | -653.799% |
| Kodiak Sciences Inc. | 277.32 Million USD | 17.54% |
| Annexon, Inc. | 143.72 Million USD | -59.112% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -79.229% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -898.21% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -35631.25% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 70.667% |
| Eyenovia, Inc. | 25.4 Million USD | -800.087% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -62.976% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -4011.471% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -188.982% |
| Arcellx, Inc. | 200.19 Million USD | -14.226% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -398.214% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -5.669% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -2196.676% |
| Moolec Science SA | 52.75 Million USD | -333.512% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -274.039% |
| Geron Corporation | 70.44 Million USD | -224.64% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -391.362% |
| Royalty Pharma plc | 862.4 Million USD | 73.483% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -143.09% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -2351.579% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -910.583% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -10.042% |
| Humacyte, Inc. | 23.49 Million USD | -873.231% |
| Structure Therapeutics Inc. | 102.77 Million USD | -122.505% |
| 89bio, Inc. | 151.2 Million USD | -51.239% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -185.379% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1472.765% |
| Genelux Corporation | 24.33 Million USD | -839.716% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -574.115% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -32.285% |
| Notable Labs, Ltd. | 14.77 Million USD | -1448.274% |
| Liquidia Corporation | 87.98 Million USD | -159.911% |
| Mustang Bio, Inc. | 48.5 Million USD | -371.495% |
| Immunovant, Inc. | 282.7 Million USD | 19.111% |
| Quantum-Si incorporated | 111.65 Million USD | -104.802% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -914.372% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -975.281% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -124.17% |
| Acasti Pharma Inc. | 11.3 Million USD | -1923.538% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -897.683% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1331.096% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -391.341% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -20055.476% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1339.506% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -684.306% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -452.581% |
| PepGen Inc. | 84.76 Million USD | -169.778% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -671.759% |
| United Therapeutics Corporation | 885.1 Million USD | 74.163% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -898.733% |
| Solid Biosciences Inc. | 104.31 Million USD | -119.221% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -598.782% |
| Immuneering Corporation | 58.41 Million USD | -291.489% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4392.523% |
| Silo Pharma, Inc. | 3.92 Million USD | -5730.913% |
| Belite Bio, Inc | 31.66 Million USD | -622.117% |
| XOMA Corporation | 46.46 Million USD | -392.177% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -238.534% |
| Bionomics Limited | 17.89 Billion USD | 98.722% |
| Apogee Therapeutics, Inc. | 93 Million USD | -145.885% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 740.919% |
| uniQure N.V. | 285.08 Million USD | 19.786% |
| Cassava Sciences, Inc. | 105.95 Million USD | -115.823% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3028.275% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -17.751% |
| Forte Biosciences, Inc. | 32.47 Million USD | -604.129% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -2652.278% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -677.955% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -4011.471% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1509.289% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -2472.618% |
| Altimmune, Inc. | 30.55 Million USD | -648.396% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 46.526% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 740.919% |
| Compugen Ltd. | 43.97 Million USD | -420.07% |
| Peak Bio, Inc. | 1249.13 USD | -18307041.771% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -208.527% |
| Benitec Biopharma Inc. | 22.38 Million USD | -921.714% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 5.966% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -701.177% |
| Zura Bio Limited | 62.63 Million USD | -265.082% |
| PolyPid Ltd. | 21.04 Million USD | -986.624% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1305.014% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -701.177% |
| Instil Bio, Inc. | 85.78 Million USD | -166.573% |
| argenx SE | 1.53 Billion USD | 85.088% |
| Immunome, Inc. | 122.82 Million USD | -86.191% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -371.768% |
| Verona Pharma plc | 67.15 Million USD | -240.545% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -783.446% |
| Shattuck Labs, Inc. | 93.61 Million USD | -144.28% |
| CervoMed Inc. | 14.95 Million USD | -1428.838% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -223.437% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -2576.498% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -348.392% |
| Moolec Science SA | 52.75 Million USD | -333.512% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1290.284% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -72.517% |
| AnaptysBio, Inc. | 181.56 Million USD | -25.947% |
| Design Therapeutics, Inc. | 78.19 Million USD | -192.467% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -162.727% |
| NeurAxis, Inc. | 8.82 Million USD | -2492.391% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1717.084% |
| Lumos Pharma, Inc. | 38.66 Million USD | -491.439% |
| Achilles Therapeutics plc | 75.25 Million USD | -203.873% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -783.446% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1596.754% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -762.864% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -7696.835% |
| Nutriband Inc. | 5.73 Million USD | -3888.119% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -106.427% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -310.903% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -349.459% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -245.966% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -322.518% |
| Palisade Bio, Inc. | 13.32 Million USD | -1616.817% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -403.601% |
| Beam Therapeutics Inc. | 554.19 Million USD | 58.736% |
| Neurogene Inc. | 55.58 Million USD | -311.421% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 7.972% |
| AEON Biopharma, Inc. | 48.42 Million USD | -372.196% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -136.46% |
| Sesen Bio, Inc. | 78.38 Million USD | -191.754% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -173.773% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1716.81% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 49.294% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -160.189% |
| Athira Pharma, Inc. | 125.46 Million USD | -82.265% |
| Vaccinex, Inc. | 23.45 Million USD | -874.973% |
| HCW Biologics Inc. | 21.02 Million USD | -987.527% |
| XOMA Corporation | 46.46 Million USD | -392.177% |
| Nektar Therapeutics | 190.9 Million USD | -19.789% |
| Arvinas, Inc. | 480 Million USD | 52.358% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -9956.421% |
| Merus N.V. | 200.49 Million USD | -14.058% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -121.257% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -560.543% |
| Rezolute, Inc. | 70.38 Million USD | -224.89% |
| Clene Inc. | 41.07 Million USD | -456.765% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1296.223% |
| BeyondSpring Inc. | 24.86 Million USD | -819.686% |
| Synlogic, Inc. | 58.53 Million USD | -290.692% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1178.113% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -4990.828% |
| Peak Bio, Inc. | 1249.13 USD | -18307041.771% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -278.321% |
| Krystal Biotech, Inc. | 160.42 Million USD | -42.545% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 15.501% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 34.295% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -10503.069% |
| MannKind Corporation | 125.59 Million USD | -82.074% |
| Ikena Oncology, Inc. | 84.57 Million USD | -170.381% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -2270.478% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -155.22% |
| Gossamer Bio, Inc. | 183.75 Million USD | -24.446% |
| CohBar, Inc. | 12.38 Million USD | -1745.936% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -350.832% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -729.091% |
| Legend Biotech Corporation | 583.14 Million USD | 60.785% |
| Mural Oncology plc | 192.07 Million USD | -19.06% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -240.566% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -1316.39% |
| Disc Medicine, Inc. | 91.12 Million USD | -150.952% |
| Champions Oncology, Inc. | 28.11 Million USD | -713.518% |
| REGENXBIO Inc. | 321.15 Million USD | 28.795% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -4165.436% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -310.144% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -486.951% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -99.97% |
| Vaxart, Inc. | 90.72 Million USD | -152.056% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -2584.035% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -434.373% |
| Cellectis S.A. | 97.32 Million USD | -134.977% |
| Longeveron Inc. | 21.25 Million USD | -976.141% |
| Repare Therapeutics Inc. | 167.35 Million USD | -36.642% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 83.195% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -202.307% |
| Revolution Medicines, Inc. | 498.76 Million USD | 54.151% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -3337.763% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -420.271% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -206.583% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -228.398% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -1967.631% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 95.211% |
| Denali Therapeutics Inc. | 527.23 Million USD | 56.626% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2541.664% |
| Veru Inc. | 101.34 Million USD | -125.638% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -876.973% |
| Cingulate Inc. | 22.75 Million USD | -904.781% |
| Passage Bio, Inc. | 108.38 Million USD | -110.981% |
| Context Therapeutics Inc. | 25.07 Million USD | -812.071% |
| Exicure, Inc. | 14.07 Million USD | -1524.609% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -10.975% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -428.117% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -2391.803% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 9.428% |
| Nuvalent, Inc. | 149.49 Million USD | -52.971% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -2734.793% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -120.627% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -966.157% |
| OmniAb, Inc. | 83.89 Million USD | -172.579% |
| Anew Medical, Inc. | 1.3 Million USD | -17479.397% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -597.961% |
| Lipocine Inc. | 15.08 Million USD | -1416.432% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -233.776% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -200.294% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -467.243% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -99.124% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -921.623% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 65.568% |
| Ocugen, Inc. | 71.56 Million USD | -219.533% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -143.624% |
| Q32 Bio Inc. | 92.68 Million USD | -146.741% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -980.004% |
| Alumis Inc. Common Stock | 158.17 Million USD | -44.575% |
| Equillium, Inc. | 50.6 Million USD | -351.883% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -266.439% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1544.523% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -1112.185% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -387.061% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -110.831% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -1745.276% |
| Dominari Holdings Inc. | 23.83 Million USD | -859.429% |
| Edesa Biotech, Inc. | 9.22 Million USD | -2379.519% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1820.551% |
| Bio-Techne Corporation | 563.03 Million USD | 59.385% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 44.061% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 14.912% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -72.88% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1486.843% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -39.698% |
| Nkarta, Inc. | 131.65 Million USD | -73.703% |
| BioCardia, Inc. | 12.12 Million USD | -1786.643% |
| Iterum Therapeutics plc | 47.46 Million USD | -381.756% |